Variability in standard care for cytomegalovirus prevention and detection in pediatric lung transplantation: Survey of eight pediatric lung transplant programs

Lara A. Danziger-Isakov, Albert Faro, Stuart Sweet, Marian G. Michaels, Paul Aurora, Peter J. Mogayzel, George B. Mallory, Debra M. Boyer, Tom B. Rice, Maite DelaMorena, Michael R. DeBaun

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) infection after pediatric lung transplantation is a significant risk factor for morbidity and mortality in the first year after transplantation. Multiple strategies have been reported for CMV prevention among adult lung transplant programs. In contrast, little information has been reported regarding protocols for prevention and detection of CMV from pediatric programs. We conducted a survey to better understand the range of practice patterns for CMV prevention and detection at pediatric lung transplant centers. A self-administered questionnaire was distributed to 11 pediatric lung transplant centers identified through the International Pediatric Lung Transplant Collaborative in September 2002. A member of the lung transplant team from each institution was asked to provide the methods of CMV prevention and surveillance. Eight of 11 centers surveyed responded to the questionnaire accounting for 45.6% (26 of 57) and 100% (three of three) of the pediatric lung transplants performed in the US and UK in 2001, respectively. All centers used prophylactic therapy against CMV with either ganciclovir or valganciclovir with duration ranging from 3.5 wk to indefinitely. Most centers (six of eight) prescribed a prophylactic regimen based on donor and recipient CMV serostatus. Half (four of eight) of the centers report using CMV hyperimmune globulin in addition to an antiviral agent. Method for CMV detection varied widely, including use of conventional viral culture (n = 1), antigenemia (n = 7), and polymerase chain reaction (n = 2). A wide range of strategies is used to prevent and detect CMV in pediatric lung transplant recipients with little empiric evidence demonstrating the optimal approach. A retrospective analysis among these centers is being conducted to evaluate the efficacy of these approaches.

Original languageEnglish (US)
Pages (from-to)469-473
Number of pages5
JournalPediatric Transplantation
Volume7
Issue number6
DOIs
StatePublished - Dec 2003

Fingerprint

Lung Transplantation
Cytomegalovirus
Pediatrics
Transplants
Lung
Surveys and Questionnaires
Ganciclovir
Globulins
Cytomegalovirus Infections
Antiviral Agents
Transplantation
Tissue Donors
Morbidity
Polymerase Chain Reaction
Mortality

Keywords

  • Cytomegalovirus
  • Lung transplantation
  • Pediatrics
  • Standard care

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

Variability in standard care for cytomegalovirus prevention and detection in pediatric lung transplantation : Survey of eight pediatric lung transplant programs. / Danziger-Isakov, Lara A.; Faro, Albert; Sweet, Stuart; Michaels, Marian G.; Aurora, Paul; Mogayzel, Peter J.; Mallory, George B.; Boyer, Debra M.; Rice, Tom B.; DelaMorena, Maite; DeBaun, Michael R.

In: Pediatric Transplantation, Vol. 7, No. 6, 12.2003, p. 469-473.

Research output: Contribution to journalArticle

Danziger-Isakov, LA, Faro, A, Sweet, S, Michaels, MG, Aurora, P, Mogayzel, PJ, Mallory, GB, Boyer, DM, Rice, TB, DelaMorena, M & DeBaun, MR 2003, 'Variability in standard care for cytomegalovirus prevention and detection in pediatric lung transplantation: Survey of eight pediatric lung transplant programs', Pediatric Transplantation, vol. 7, no. 6, pp. 469-473. https://doi.org/10.1046/j.1397-3142.2003.00102.x
Danziger-Isakov, Lara A. ; Faro, Albert ; Sweet, Stuart ; Michaels, Marian G. ; Aurora, Paul ; Mogayzel, Peter J. ; Mallory, George B. ; Boyer, Debra M. ; Rice, Tom B. ; DelaMorena, Maite ; DeBaun, Michael R. / Variability in standard care for cytomegalovirus prevention and detection in pediatric lung transplantation : Survey of eight pediatric lung transplant programs. In: Pediatric Transplantation. 2003 ; Vol. 7, No. 6. pp. 469-473.
@article{105c7625a6914ad0ac5c3a0ed2d2c720,
title = "Variability in standard care for cytomegalovirus prevention and detection in pediatric lung transplantation: Survey of eight pediatric lung transplant programs",
abstract = "Cytomegalovirus (CMV) infection after pediatric lung transplantation is a significant risk factor for morbidity and mortality in the first year after transplantation. Multiple strategies have been reported for CMV prevention among adult lung transplant programs. In contrast, little information has been reported regarding protocols for prevention and detection of CMV from pediatric programs. We conducted a survey to better understand the range of practice patterns for CMV prevention and detection at pediatric lung transplant centers. A self-administered questionnaire was distributed to 11 pediatric lung transplant centers identified through the International Pediatric Lung Transplant Collaborative in September 2002. A member of the lung transplant team from each institution was asked to provide the methods of CMV prevention and surveillance. Eight of 11 centers surveyed responded to the questionnaire accounting for 45.6{\%} (26 of 57) and 100{\%} (three of three) of the pediatric lung transplants performed in the US and UK in 2001, respectively. All centers used prophylactic therapy against CMV with either ganciclovir or valganciclovir with duration ranging from 3.5 wk to indefinitely. Most centers (six of eight) prescribed a prophylactic regimen based on donor and recipient CMV serostatus. Half (four of eight) of the centers report using CMV hyperimmune globulin in addition to an antiviral agent. Method for CMV detection varied widely, including use of conventional viral culture (n = 1), antigenemia (n = 7), and polymerase chain reaction (n = 2). A wide range of strategies is used to prevent and detect CMV in pediatric lung transplant recipients with little empiric evidence demonstrating the optimal approach. A retrospective analysis among these centers is being conducted to evaluate the efficacy of these approaches.",
keywords = "Cytomegalovirus, Lung transplantation, Pediatrics, Standard care",
author = "Danziger-Isakov, {Lara A.} and Albert Faro and Stuart Sweet and Michaels, {Marian G.} and Paul Aurora and Mogayzel, {Peter J.} and Mallory, {George B.} and Boyer, {Debra M.} and Rice, {Tom B.} and Maite DelaMorena and DeBaun, {Michael R.}",
year = "2003",
month = "12",
doi = "10.1046/j.1397-3142.2003.00102.x",
language = "English (US)",
volume = "7",
pages = "469--473",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Variability in standard care for cytomegalovirus prevention and detection in pediatric lung transplantation

T2 - Survey of eight pediatric lung transplant programs

AU - Danziger-Isakov, Lara A.

AU - Faro, Albert

AU - Sweet, Stuart

AU - Michaels, Marian G.

AU - Aurora, Paul

AU - Mogayzel, Peter J.

AU - Mallory, George B.

AU - Boyer, Debra M.

AU - Rice, Tom B.

AU - DelaMorena, Maite

AU - DeBaun, Michael R.

PY - 2003/12

Y1 - 2003/12

N2 - Cytomegalovirus (CMV) infection after pediatric lung transplantation is a significant risk factor for morbidity and mortality in the first year after transplantation. Multiple strategies have been reported for CMV prevention among adult lung transplant programs. In contrast, little information has been reported regarding protocols for prevention and detection of CMV from pediatric programs. We conducted a survey to better understand the range of practice patterns for CMV prevention and detection at pediatric lung transplant centers. A self-administered questionnaire was distributed to 11 pediatric lung transplant centers identified through the International Pediatric Lung Transplant Collaborative in September 2002. A member of the lung transplant team from each institution was asked to provide the methods of CMV prevention and surveillance. Eight of 11 centers surveyed responded to the questionnaire accounting for 45.6% (26 of 57) and 100% (three of three) of the pediatric lung transplants performed in the US and UK in 2001, respectively. All centers used prophylactic therapy against CMV with either ganciclovir or valganciclovir with duration ranging from 3.5 wk to indefinitely. Most centers (six of eight) prescribed a prophylactic regimen based on donor and recipient CMV serostatus. Half (four of eight) of the centers report using CMV hyperimmune globulin in addition to an antiviral agent. Method for CMV detection varied widely, including use of conventional viral culture (n = 1), antigenemia (n = 7), and polymerase chain reaction (n = 2). A wide range of strategies is used to prevent and detect CMV in pediatric lung transplant recipients with little empiric evidence demonstrating the optimal approach. A retrospective analysis among these centers is being conducted to evaluate the efficacy of these approaches.

AB - Cytomegalovirus (CMV) infection after pediatric lung transplantation is a significant risk factor for morbidity and mortality in the first year after transplantation. Multiple strategies have been reported for CMV prevention among adult lung transplant programs. In contrast, little information has been reported regarding protocols for prevention and detection of CMV from pediatric programs. We conducted a survey to better understand the range of practice patterns for CMV prevention and detection at pediatric lung transplant centers. A self-administered questionnaire was distributed to 11 pediatric lung transplant centers identified through the International Pediatric Lung Transplant Collaborative in September 2002. A member of the lung transplant team from each institution was asked to provide the methods of CMV prevention and surveillance. Eight of 11 centers surveyed responded to the questionnaire accounting for 45.6% (26 of 57) and 100% (three of three) of the pediatric lung transplants performed in the US and UK in 2001, respectively. All centers used prophylactic therapy against CMV with either ganciclovir or valganciclovir with duration ranging from 3.5 wk to indefinitely. Most centers (six of eight) prescribed a prophylactic regimen based on donor and recipient CMV serostatus. Half (four of eight) of the centers report using CMV hyperimmune globulin in addition to an antiviral agent. Method for CMV detection varied widely, including use of conventional viral culture (n = 1), antigenemia (n = 7), and polymerase chain reaction (n = 2). A wide range of strategies is used to prevent and detect CMV in pediatric lung transplant recipients with little empiric evidence demonstrating the optimal approach. A retrospective analysis among these centers is being conducted to evaluate the efficacy of these approaches.

KW - Cytomegalovirus

KW - Lung transplantation

KW - Pediatrics

KW - Standard care

UR - http://www.scopus.com/inward/record.url?scp=10744221566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744221566&partnerID=8YFLogxK

U2 - 10.1046/j.1397-3142.2003.00102.x

DO - 10.1046/j.1397-3142.2003.00102.x

M3 - Article

C2 - 14870896

AN - SCOPUS:10744221566

VL - 7

SP - 469

EP - 473

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 6

ER -